This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Syneos Health's (SYNH) New Pact Boosts Tech-Driven Solutions
by Zacks Equity Research
Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.
Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion
by Zacks Equity Research
Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.
Veeva Systems' (VEEV) Deal to Enhance Digital Clinical Trials
by Zacks Equity Research
Veeva Systems' (VEEV) partnership with Leo Pharma to significantly boost the clinical trial process for patients, sites and sponsors.
Veeva (VEEV) Down 8.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.
Veeva Systems' (VEEV) New Offering to Optimize Lab Operations
by Zacks Equity Research
Veeva Systems' (VEEV) Vault LIMS is expected to help manufacturers optimize lab management and significantly simplify their systems landscape via a unified suite of quality and lab applications.
Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes
by Zacks Equity Research
Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
by Debanjana Dey
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
Veeva Systems (VEEV) Q2 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both its segments.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 9.30% and 0.96%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials
by Zacks Equity Research
Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Veeva Systems (VEEV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Veeva (VEEV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veeva Systems (VEEV) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal second-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Veeva Systems (VEEV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $322.44, marking a +0.54% move from the previous day.
Veeva Systems (VEEV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $319.22, marking a -0.8% move from the previous day.
Veeva Systems (VEEV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $332.34 in the latest trading session, marking a -1.91% move from the prior day.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $332.78 in the latest trading session, marking a +0.02% move from the prior day.
Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
by Zacks Equity Research
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.
PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Bear of the Day: Sabre Corp. (SABR)
by Madeleine Johnson
Covid-19 is still weighing on this travel technology provider.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod
by Zacks Equity Research
Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.
MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on
by Debanjana Dey
Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.
Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product
by Zacks Equity Research
Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.